Elser Financial Planning Inc Acquires 2,498 Shares of Johnson & Johnson (NYSE:JNJ)

Elser Financial Planning Inc increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 40.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,621 shares of the company's stock after buying an additional 2,498 shares during the quarter. Johnson & Johnson accounts for about 2.0% of Elser Financial Planning Inc's holdings, making the stock its 11th biggest holding. Elser Financial Planning Inc's holdings in Johnson & Johnson were worth $1,430,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the fourth quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at about $38,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.6%

NYSE JNJ opened at $149.81 on Friday. The business has a 50 day simple moving average of $154.07 and a 200 day simple moving average of $153.65. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The stock has a market capitalization of $360.44 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JNJ shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.